LUNDBECK, LLC
Clinical Trials
9
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms
- First Posted Date
- 2011-08-10
- Last Posted Date
- 2012-09-13
- Lead Sponsor
- Lundbeck LLC
- Registration Number
- NCT01413711
A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Lundbeck LLC
- Target Recruit Count
- 65
- Registration Number
- NCT01278173
- Locations
- 🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸Yale Medical Center, New Haven, Connecticut, United States
🇺🇸CNMRI, Dover, Delaware, United States
Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2018-03-21
- Lead Sponsor
- Lundbeck LLC
- Target Recruit Count
- 267
- Registration Number
- NCT01160770
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Lundbeck LLC
- Target Recruit Count
- 108
- Registration Number
- NCT01128959
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Clinical Trials Incorporated, Little Rock, Arkansas, United States
🇺🇸Collaborative Neuroscience Network, Inc., Torrance, California, United States
A Study of the Pharmacokinetics (PK) and Safety of IV Carbamazepine Relative to Oral Carbamazepine in Adults With Epilepsy
- Conditions
- Epilepsy
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2010-04-23
- Lead Sponsor
- Lundbeck LLC
- Target Recruit Count
- 98
- Registration Number
- NCT01079351
- Prev
- 1
- 2
- Next
News
Lundbeck's Lu AG13909 Receives Orphan Drug Designation for Congenital Adrenal Hyperplasia Treatment
Lundbeck received orphan drug designation from both the FDA and EMA for Lu AG13909, a novel humanized monoclonal antibody targeting ACTH for congenital adrenal hyperplasia treatment.
Lundbeck's Eptinezumab Shows Strong Efficacy in Asian Chronic Migraine Patients in Phase III SUNRISE Trial
H. Lundbeck A/S announced positive results from the SUNRISE phase III trial, demonstrating eptinezumab's efficacy in a predominantly Asian population with chronic migraine.
Pharmaceutical Industry Sees Wave of Board Appointments as Companies Strengthen Leadership
Pharmaceutical and biotech companies across Europe and North America have made significant board appointments, bringing industry veterans and scientific experts to strengthen their leadership teams.
Lundbeck Presents Phase II Data for Amlenetug in Multiple System Atrophy at International Congress
Lundbeck presented results from the AMULET phase II trial investigating amlenetug, a monoclonal antibody targeting α-synuclein, as a potential treatment for multiple system atrophy (MSA).
Migraine Treatment Pipeline Shows Robust Activity with 30+ Companies Advancing Novel Therapies Through Clinical Trials
DelveInsight's 2025 pipeline report reveals over 30 companies are actively developing more than 30 pipeline therapies for migraine treatment, indicating a robust therapeutic landscape.
Lundbeck's Vyepti Demonstrates Sustained Efficacy in Migraine Prevention at AAN 2025
New data presented at AAN 2025 shows Lundbeck's Vyepti provides sustained efficacy for migraine prevention, with significant improvements in patient-reported outcomes including brain fog reduction.
FDA Accepts Teva's Application for AJOVY in Pediatric Migraine Prevention, Potentially First CGRP Antagonist for Children
The FDA has accepted Teva Pharmaceuticals' supplemental Biologics License Application for AJOVY (fremanezumab) to expand its indication to include prevention of episodic migraine in children and adolescents aged 6-17 years weighing at least 45 kg.
Lundbeck Expands PROCEED Trial to Include Intravenous Administration of Novel Anti-PACAP Antibody for Migraine Prevention
Following a planned interim analysis of the Phase IIb PROCEED trial, Lundbeck will expand testing of Lu AG09222, a first-in-class anti-PACAP monoclonal antibody, to include intravenous administration for migraine prevention.
European Commission Approves Rxulti for Adolescent Schizophrenia Treatment
The European Commission has approved Rxulti (brexpiprazole) for treating schizophrenia in adolescents aged 13 years and older, expanding its previous 2018 approval for adults.
Bipolar Depression Market Set to Grow Through 2034 with New Therapies in Pipeline
• The global bipolar depression market is projected to experience significant growth through 2034, driven by increasing prevalence, with the United States accounting for approximately 85% of the market share across major regions. • Several pharmaceutical companies including NeuroRx, COMPASS Pathways, and Intra-Cellular Therapies are advancing novel treatments, with Johnson & Johnson's recent $14.6 billion acquisition of Intra-Cellular Therapies highlighting industry confidence in the sector. • Among current therapies, CAPLYTA (lumateperone) is expected to achieve the highest market share by 2034, while emerging treatments like NRX-100/101 and COMP 360 (psilocybin) show promise for addressing unmet needs in bipolar depression management.